Noah Stansfield

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial.

The head of the clinical development program at Galapagos discussed the company's data presented at EHA's 2025 Congress.

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine, discussed safety and efficacy data from a phase 1 trial for Kite's CD19/CD20-directed CAR-T.

Review top news and interview highlights from the week ending June 13, 2025.

The overall response rate for the 11 treated patients was 72.7% at 3 months posttreatment.

The study included 3 boys and 6 girls who were treated with gene therapy for TDT at 5 to 16 years of age.

The data, from a study of 15 patients, were presented at EHA’s 2025 Congress.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed the implications of findings from a deidentified database of EMR data.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In light of the IND clearance, the company intends to go forward with plans for a first-in-human phase 1/2 ascending-dose clinical trial.

The platform technology designation is a new designation established by the FDA.

The principal scientist at Bristol Myers Squibb discussed a biomarker analysis she presented at ASCO's 2025 meeting.

The hematologist/oncologist at the Cleveland Clinic discussed next steps after early promising results were presented at ASCO’s 2025 meeting.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the implications of a large scale analysis of liso-cel recipients.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Review top news and interview highlights from the week ending June 6, 2025.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado discussed the implications of a large scale analysis of liso-cel recipients.

The MSKCC Amyloidosis Program director and NEXICART-2 principal study investigator discussed results she presented at ASCO's 2025 meeting.

The hematologist/oncologist at the Cleveland Clinic discussed early results from a clinical trial evaluating the BCMA-directed CAR-T therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The analysis included 153 patients with a median follow-up of 57.8 months.

Following treatment with NXC-201, all 7 patients (100%) showed normalized pathological disease markers.

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center, discussed her presentation at ASCO this year.

The associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado discussed an analysis of more than 1,500 patients treated with liso-cel across clinical trials and the real world.

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed phase 1 data on the company’s autologous dendritic cell immunotherapy.

The chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

The program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center discussed her presentation at ASCO this year.

Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences, discussed the company’s trial design presentation at ASCO’s 2025 meeting.